Christine Lovly

May 11, 2023

Lovly elected to American Association for Cancer Research board

Christine Lovly, MD, PhD, has been elected to the American Association for Cancer Research board of directors.

By Tom Wilemon
May 11, 2023

Genomic analysis of SCLC tumors reveals subtypes, offers cues toward personalized treatments

The largest genomic analysis ever conducted of small cell lung cancer tumors (SCLC) has identified genetic subtypes and provided insights into the mechanisms of this aggressive and deadly cancer.

By Tom Wilemon
December 8, 2022

Lovly receives Asclepios Award from GO2 for Lung Cancer

Vanderbilt’s Christine Lovly, MD, PhD, has received the 2022 Asclepios Award, which recognizes lung cancer research pioneers.

By Tom Wilemon
July 28, 2022

Study reveals need for matching targeted therapies with EGFR subtypes

A Vanderbilt study suggests that clinicians should take a deeper dive into distinguishing EGFR mutations when prescribing targeted therapies for non-small-cell lung cancers.

By Tom Wilemon
June 9, 2021

Christine Lovly 2021 recipient of the ECOG-ACRIN Young Investigator Award

Christine Lovly, MD, PhD, is the recipient of the 2021 ECOG-ACRIN Young Investigator Award, a major recognition of research excellence.

By VUMC News and Communications
May 26, 2021

Vanderbilt researchers present new data on clinical trials at ASCO 2021

Vanderbilt-Ingram Cancer Center researchers will present data on clinical trials involving targeted therapies, immunotherapies and drug combination synergies at the 2021 American Society of Clinical Oncology Annual Meeting, June 4-8. The meeting is a virtual event this year.

By Tom Wilemon
April 8, 2021

Personalized Structural Biology aids cancer treatment decisions

Cancer specialists at Vanderbilt University Medical Center, in partnership with biochemists and structural biologists across the Vanderbilt University campus, are taking “personalized” cancer therapy to a new level.
By Bill Snyder
March 18, 2021

EGFR Resisters/LUNGevity fund lung cancer research

Christine Lovly, MD, PhD, associate professor of Medicine in the Division of Hematology and Oncology and Ingram Professor of Cancer Research, is one of two inaugural recipients of the EGFR Resisters/LUNGevity Lung Cancer Research Award.
By Tom Wilemon
February 25, 2021

Gift in memory of Phran Galante boosts lung cancer research

A gift in memory of music industry executive and community philanthropist Phran Galante will support the work of Christine Lovly, MD, PhD, associate professor of Medicine and Ingram Professor of Cancer Research, to improve targeted therapies for lung cancer.
By Tom Wilemon
October 29, 2020

Lovly to chair foundation’s scientific leadership board

Christine Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, has been named incoming chair of GO2 Foundation's Scientific Leadership Board (SLB).
By Tom Wilemon
October 1, 2020

Diversity role model inspires career path

Portia Thomas grew up in Doerun, Georgia, a small, rural city named by pioneer hunters as a place with “a perfect doe run,” where the population has hovered around 800 people for the past 30 years. A childhood impression lifted her aspirations beyond her hometown and inspired her to pursue a career as a physician-scientist.
By Tom Wilemon
February 13, 2020

Advocacy group’s gift boosts lung cancer research efforts

An advocacy group for patients with anaplastic lymphoma kinase positive lung cancer has awarded a $500,000 grant dedicated to overcoming treatment resistance to the cancer.
By Tom Wilemon
April 11, 2019

Study reframes approach to targeted therapy resistance

When a tumor mutates and develops resistance to a targeted therapy, researchers often focus on the acquisition of new mutations within the drug target as they seek an alternative treatment, but a team of Vanderbilt scientists has shown this may not be sufficient.
By Tom Wilemon